Fermenta Biotec.

Why is Fermenta Biotech Ltd falling/rising?

As of 01-Jul, Fermenta Biotech Ltd's stock price is declining, with a 3-day drop of -3.01% and a significant decrease in investor participation. Despite a 7.34% return over the past year, the company faces financial challenges, including negative profits and weak growth prospects.

As of 01-Jul, Fermenta Biotech Ltd's stock price is currently falling, with a change of -0.4, representing a decline of -0.11%. The stock has been experiencing a consecutive fall for the last three days, resulting in a total decrease of -3.01% during this period. Additionally, the stock's performance today is described as inline with the sector, but it is noteworthy that the stock has shown a significant drop in investor participation, with delivery volume falling by -40.51% compared to the 5-day average.<BR><BR>Despite a positive return of 7.34% over the past year, the company's profits have decreased by -13%, indicating underlying financial challenges. The company has also reported negative results for the last two consecutive quarters, with a particularly low operating profit margin and a significant decline in net sales of -13.06%. Furthermore, the stock is trading at a discount compared to its peers' average historical valuations, which may reflect investor concerns about its long-term growth potential, especially given the weak long-term fundamental strength indicated by an average Return on Capital Employed (ROCE) of only 8.88%.<BR><BR>Overall, the combination of declining investor interest, negative financial results, and weak growth prospects contributes to the current downward trend in Fermenta Biotech Ltd's stock price.

Which are the latest news on Fermenta Biotec.?

Should I buy, sell or hold Fermenta Biotech Ltd?

How big is Fermenta Biotec.?

As of 10th June, Fermenta Biotech Ltd has a market capitalization of 998.00 Cr, with recent net sales of 525.42 Cr and a net profit of 71.76 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Fermenta Biotech Ltd has a market capitalization of 998.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 525.42 Cr, while the sum of Net Profit for the same period is 71.76 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 362.67 Cr, and Total Assets are valued at 585.83 Cr.

Who are in the management team of Fermenta Biotec.?

The management team of Fermenta Biotec includes Krishna Datla (Executive Chairman), Prashant Nagre (Managing Director), Satish Varma, Anupama Datla Desai, Srikant N Sharma (Company Secretary), Rajeshwari Datla, and several independent directors, including Sanjay Buch and Vinayak Hajare. This diverse team contributes to the company's strategic direction and governance.

The management team of Fermenta Biotec includes the following individuals:<BR><BR>1. **Krishna Datla** - Executive Chairman & Whole-Time Director<BR>2. **Prashant Nagre** - Managing Director<BR>3. **Satish Varma** - Executive Director<BR>4. **ANUPAMA DATLA DESAI** - Executive Director<BR>5. **Srikant N Sharma** - Company Secretary & Compliance Officer<BR>6. **Rajeshwari Datla** - Director<BR>7. **Sanjay Buch** - Chairman & Independent Director<BR>8. **Vinayak Hajare** - Independent Director<BR>9. **Gopakumar G Nair** - Independent Director<BR>10. **Rajashri Santosh Kumar Ojha** - Independent Director<BR>11. **Pramod Kasat** - Independent Director<BR><BR>This team brings a diverse range of expertise to the company, contributing to its strategic direction and governance.

Who are the peers of the Fermenta Biotec.?

Fermenta Biotec's peers include Shukra Pharma, Jagsonpal Pharma, Lincoln Pharma, Fredun Pharma, Bajaj Healthcare, Themis Medicare, Bharat Parenter, Wanbury, and Kopran. In terms of performance, Fermenta Biotec has a 1-year return of -1.52%, better than Bajaj Healthcare's -44.41% but worse than Fredun Pharma's 211.49%.

Peers: The peers of Fermenta Biotec. are Shukra Pharma., Jagsonpal Pharma, Lincoln Pharma., Fredun Pharma, Bajaj Healthcare, Themis Medicare, Bharat Parenter., Wanbury, and Kopran.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shukra Pharma., while Average management risk is found at Jagsonpal Pharma, Lincoln Pharma., Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Wanbury, and Kopran. Growth is Excellent at Shukra Pharma. and Fredun Pharma, while Below Average growth is noted for Jagsonpal Pharma, Lincoln Pharma., Fermenta Biotec., Themis Medicare, Bharat Parenter., Wanbury, and Kopran, and the rest. Capital Structure is Excellent at Shukra Pharma. and Lincoln Pharma., while Below Average is seen at Fredun Pharma, Bajaj Healthcare, and Fermenta Biotec., with Average at Bharat Parenter. and the rest.<BR><BR>Return Snapshot: Fredun Pharma has the highest 1-year return at 211.49%, while Bajaj Healthcare has the lowest at -44.41%. Fermenta Biotec. has a 1-year return of -1.52%, which is better than Bajaj Healthcare but worse than Fredun Pharma. Additionally, Bajaj Healthcare, Themis Medicare, and Wanbury have negative six-month returns.

What does Fermenta Biotec. do?

Fermenta Biotech Ltd manufactures and markets chemicals, bulk drugs, enzymes, and pharmaceutical formulations within the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of ₹122 Cr and a net profit of ₹19 Cr, with a market cap of ₹998 Cr.

Overview:<BR>Fermenta Biotech Ltd is engaged in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History:<BR>The company was incorporated in May 1951 as 'Duphar-Interfran Limited', later changing its name to 'DIL Limited' in September 2003, and finally to 'Fermenta Biotech Limited' on October 17, 2019. The most recent quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 122 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 19 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 998 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 15.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.73%<BR>- Debt-Equity: 0.18<BR>- Return on Equity: 16.45%<BR>- Price to Book: 2.48<BR><BR>Contact Details:<BR>Address: A-1501 DIL Complex Majiwada, Ghodbunder Road Thane One Thane (West) Maharashtra : 400610<BR>Tel: 91-22-66230800/888<BR>Email: srikant.sharma@dil.net; contact@dil<BR>Website: http://www.fermentabiotech.com

Are Fermenta Biotech Ltd latest results good or bad?

Fermenta Biotech Ltd's latest results are poor, with a 44.20% year-on-year decline in net profit and a 13.06% drop in net sales, marking four consecutive quarters of revenue decline and a significant deterioration in operating margins. The company's stock has also declined 15.86% year-to-date, raising concerns about its operational and profitability outlook.

Fermenta Biotech Ltd's latest results indicate a challenging situation for the company. In the fourth quarter of FY26, the company reported a consolidated net profit of ₹19.19 crores, which represents a significant decline of 44.20% year-on-year. Additionally, net sales fell to ₹121.58 crores, down 13.06% compared to the same quarter last year, marking the fourth consecutive quarter of revenue decline.<BR><BR>The operating margin has also deteriorated sharply, collapsing to 16.45%, down from 26.41% in the previous year, which is the lowest level in eight quarters. This margin compression, coupled with weak profitability metrics, has raised concerns among investors.<BR><BR>While there was a sequential improvement in net profit compared to the previous quarter, the overall year-on-year performance reflects ongoing operational challenges. The stock has declined 15.86% year-to-date and is currently trading in a bearish technical trend. Overall, the results can be characterized as poor, with significant concerns about the company's ability to maintain operational momentum and profitability moving forward.

When is the next results date for Fermenta Biotech Ltd?

The next results date for Fermenta Biotech Ltd is 26 May 2026.

The next results date for Fermenta Biotech Ltd is scheduled for 26 May 2026.

Is Fermenta Biotec. technically bullish or bearish?

As of November 17, 2025, Fermenta Biotec's technical trend has shifted to a moderate bearish stance, supported by bearish MACD, moving averages, Bollinger Bands, and KST indicators, with the RSI showing no momentum signals.

As of 17 November 2025, the technical trend for Fermenta Biotec has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this conclusion include a bearish MACD on the weekly chart and a bearish reading on the daily moving averages. Additionally, Bollinger Bands and KST are both bearish on the weekly timeframe, further supporting the bearish outlook. The RSI shows no signals on both weekly and monthly timeframes, indicating a lack of momentum. Overall, the technical indicators suggest a negative sentiment in the market for Fermenta Biotec.

How has been the historical performance of Fermenta Biotec.?

Fermenta Biotec has shown a recovery in financial performance, with net sales increasing from 335.66 Cr in Mar'24 to 469.48 Cr in Mar'25, leading to a profit after tax of 76.40 Cr, a turnaround from a loss the previous year. However, total expenditure also rose, and cash flow from operating activities decreased.

Answer:<BR>The historical performance of Fermenta Biotec shows a fluctuating trend over the years, with significant changes in net sales, profits, and overall financial health.<BR><BR>Breakdown:<BR>Fermenta Biotec's net sales increased from 335.66 Cr in Mar'24 to 469.48 Cr in Mar'25, marking a notable recovery from previous years. The total operating income followed a similar trend, rising to 469.48 Cr in Mar'25 from 335.66 Cr in Mar'24. However, total expenditure also increased, reaching 359.68 Cr in Mar'25, up from 308.15 Cr in Mar'24. This led to an operating profit (PBDIT) of 121.62 Cr in Mar'25, a substantial increase from 39.32 Cr in the previous year. Profit before tax turned positive at 83.21 Cr in Mar'25, compared to a loss of 9.87 Cr in Mar'24, resulting in a profit after tax of 76.40 Cr, a significant turnaround from the loss of 24.01 Cr in Mar'24. The company's total assets increased to 585.83 Cr in Mar'25 from 525.83 Cr in Mar'24, while total liabilities also rose to 585.83 Cr from 525.83 Cr, indicating a stable financial position. Cash flow from operating activities decreased to 40.00 Cr in Mar'25 from 105.00 Cr in Mar'24, contributing to a net cash outflow of 10.00 Cr in Mar'25. Overall, the company has shown signs of recovery in its financial performance, particularly in sales and profitability.

Is Fermenta Biotec. overvalued or undervalued?

As of October 1, 2025, Fermenta Biotec is considered very attractive for investment due to its undervalued status, highlighted by a PE ratio of 9.21 and strong growth potential, despite a recent decline in stock performance compared to the Sensex.

As of 1 October 2025, the valuation grade for Fermenta Biotec has moved from attractive to very attractive, indicating a strong improvement in its investment appeal. The company is currently assessed as undervalued, supported by a PE ratio of 9.21, an EV to EBITDA of 7.33, and a PEG ratio of 0.02, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, Fermenta Biotec's valuation metrics stand out; for instance, Sun Pharma has a PE ratio of 34.22 and an EV to EBITDA of 23.17, while Cipla shows a PE of 22.63 and an EV to EBITDA of 15.9, both indicating higher valuations than Fermenta. Notably, Fermenta's ROCE and ROE are strong at 21.08% and 21.19%, respectively, further reinforcing its undervalued status. Despite a recent decline in stock performance compared to the Sensex, with a YTD return of -10.15% versus the Sensex's 3.64%, the long-term outlook remains positive, evidenced by a 3-year return of 57.86%.

Who are the top shareholders of the Fermenta Biotec.?

The top shareholders of Fermenta Biotec include promoter Krishna Datla with 36.04%, individual investors holding 30.38%, and public shareholder Rakesh Kantilal Shah with 2.04%. There are no pledged promoter holdings, and foreign institutional investors hold a total of 0.02%.

The top shareholders of Fermenta Biotec include the promoters, with Krishna Datla holding the highest share at 36.04%. There are no pledged promoter holdings, and individual investors collectively hold 30.38% of the shares. Additionally, Rakesh Kantilal Shah is the highest public shareholder with a stake of 2.04%. The company also has two foreign institutional investors (FIIs) holding a total of 0.02%.

What is the bonus history of the Fermenta Biotec.?

Fermenta Biotec has issued bonuses twice in recent years: a 2:1 bonus on February 13, 2020, and a 1:1 bonus on August 8, 2018, reflecting a consistent practice of rewarding shareholders.

Fermenta Biotec has a history of bonus issues that includes two significant events. The latest bonus was a 2:1 issue announced on February 13, 2020, with a record date of February 14, 2020. Prior to that, the company issued a 1:1 bonus on August 8, 2018, with a record date of August 9, 2018. This indicates a pattern of rewarding shareholders through bonus shares in recent years.

Has Fermenta Biotec. declared dividend?

Fermenta Biotech Ltd has declared a 25% dividend, amounting to ₹1.25 per share, with an ex-date of August 6, 2024. While the dividend yield is 0.39%, total returns have been notably positive over the 1-year (103.61%) and 2-year (130.15%) periods.

Fermenta Biotech Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 1.25<BR>- Ex-date: 06 Aug 24<BR><BR>Dividend Yield: 0.39%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -20.96%, the dividend return was 0%, resulting in a total return of -20.96%.<BR><BR>For the 1-year period, the price return was 102.83%, the dividend return was 0.78%, leading to a total return of 103.61%.<BR><BR>Over the 2-year period, the price return was 128.37%, the dividend return was 1.78%, culminating in a total return of 130.15%.<BR><BR>In the 3-year period, the price return was 58.35%, the dividend return was 1.97%, which resulted in a total return of 60.32%.<BR><BR>During the 4-year period, the price return was -0.37%, the dividend return was 1.89%, giving a total return of 1.52%.<BR><BR>For the 5-year period, the price return was 30.76%, the dividend return was 2.40%, resulting in a total return of 33.16%.<BR><BR>Overall, Fermenta Biotech Ltd has declared a dividend, and while the dividend yield is relatively low, the total returns over longer periods show significant positive growth, particularly in the 1-year and 2-year periods.